CORT · Corcept Therapeutics Incorporated

The thesis

Corcept Therapeutics' case still rests on Lifyorli, its ovarian-cancer drug, turning a $47.6 million first quarter into repeatable sales. The Q3 2026 report (about 30 October 2026, estimated) and the 17 December 2026 U.S. decision on relacorilant for Cushing's syndrome settle it. The shares closed at $107.50 on 22 October 2026, below the $108 close level the 10 October 2026 note named as the break point, and 13.0% under the 52-week high of $123.57.

Corcept raised 2026 revenue guidance to $1.1–$1.2 billion on 29 July 2026, from $950 million–$1.05 billion. The consensus estimate then was $1.008 billion, per Benzinga. No second Lifyorli quarter has been reported yet, so the guidance rests on one data point. The narrative is maturing: the launch story has been well known since the 29 July 2026 report, and the shares have moved from a $121.19 close on 9 October 2026 to $107.50 with no company report in between.

Bullish and bearish views on Corcept Therapeutics Incorporated

The bull case on Corcept Therapeutics Incorporated (CORT), in brief: Guidance sits well above prior expectations. The bear case: One launch quarter is a thin sample.

Bull case

• Guidance sits well above prior expectations. Corcept's 2026 revenue range of $1.1–$1.2 billion compares with the $1.008 billion consensus estimate Benzinga cited on 29 July 2026. Q2 revenue was $256.147 million against a $219.988 million estimate.
• Lifyorli has a measured launch quarter. Corcept's Q2 release showed $47.6 million in the drug's first quarter of availability. A Q3 figure above that would be the first evidence of a ramp.
• Korlym demand got a clinical endorsement. On 20 October 2026 Corcept announced that a joint American Diabetes Association and European Association for the Study of Diabetes consensus report recommends screening for hypercortisolism in difficult-to-control type 2 diabetes. Corcept cited its CATALYST trial of mifepristone, the active ingredient in Korlym, in the announcement.
• Europe advanced a step. The European Medicines Agency's human-medicines committee recommended relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer on 18 September 2026. The European Commission decision is pending in Q4 2026.
• Sell-side targets remain far above the price. Piper Sandler and HC Wainwright set $165 targets and Canaccord Genuity set $161 on 30 July 2026, per Benzinga. Benzinga's quote page lists a consensus target of $127.17.

Bear case

• One launch quarter is a thin sample. The $47.6 million Lifyorli figure covers a single quarter. Q3 revenue at or below it would challenge the growth case.
• The Cushing's application failed once. Corcept disclosed a complete response letter from the FDA on 27 May 2026 and resubmitted on 17 June 2026. The FDA target date is 17 December 2026.
• The shares have broken lower into earnings. The close of $107.50 on 22 October 2026 compares with $116.10 on 25 September 2026 and $121.19 on 9 October 2026. The 14-day relative strength index (RSI, a 0–100 momentum gauge) reads 38.6, and no news item dated after 9 October 2026 explains the decline.
• Sell-side views are split. Wolfe Research downgraded the shares to Underperform with a $50 target on 27 July 2026, per Benzinga.
• A director sold near the high. Kimberly Park sold 26,685 shares at a $122.5471 weighted-average price, per an SEC Form 4 dated 26 August 2026.
• Litigation continues. A securities class action and an amended former-employee complaint filed 3 June 2026 remain live.

Price setup

Adjusted daily closes show $116.10 on 25 September 2026, $121.19 on 9 October 2026 and $107.50 on 22 October 2026. The 52-week high is $123.57. The shares are up 18.0% over three months, a much smaller gain than the 34.0% three-month gain reported in the 10 October 2026 note. The close sits under the $108 level that note flagged.

Crowding evidence is limited. The RSI of 38.6 shows weak momentum, not an extended run. The Q3 report is about a week away, and the company had not confirmed the date as of 23 October 2026. Institutional and hedge-fund ownership was 93.61% in August 2026, per MarketBeat. The one insider sale on file is the director's 26 August 2026 sale.

Catalysts, next 30 days

• 17 December 2026: FDA target action date for relacorilant in Cushing's syndrome. Approval would add a second indication. A second nonapproval would remove it.

Elapsed catalysts

• ~30 October 2026 (est.): Q3 2026 results and conference call. An aggregator lists this date, and Q3 2025 was reported 4 November 2025. The report shows whether Lifyorli revenue exceeds $47.6 million and whether Korlym holds near the $208.6 million of Q2. (passed 7d ago)
• Q4 2026: European Commission decision on relacorilant in ovarian cancer. The committee opinion of 18 September 2026 makes approval the expected outcome. (passed 49d ago)

What would change the view

The case breaks if Q3 Lifyorli revenue is at or below the $47.6 million reported for Q2 2026, because that would show the first quarter was a stocking or backlog effect. A second FDA nonapproval on 17 December 2026 or a negative European Commission decision would also break it. Korlym revenue falling well below the $208.6 million of Q2 2026 would weaken the older business that funds the launch.

On price, a daily close below $100 would take the shares well under the October range. The $108 close level named on 10 October 2026 has already been breached, so the rating stays at the coverage level until the Q3 report adds a second Lifyorli data point.

What it trades with

Corcept trades mainly on its own launch and regulatory dates, not on a sector basket. Mid-cap biotech indices and broad risk appetite move it on days without company news. Korlym's mifepristone ingredient adds exposure to U.S. political and regulatory headlines that are unrelated to oncology.